Journal of Clinical Oncology

دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه

ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
~~قیمت : 3,800,000 تومان~~
قیمت ویژه : 1,900,000تومان

سفارش

Primary Tumor Resection in Colorectal Cancer With Synchronous Unresectable Metastasis: Time to End the Debate?

George J. Chang , MD, MS1

doi : 10.1200/JCO.21.00057

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1095-1097.

خرید پکیج و مشاهده آنلاین مقاله

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial

Yukihide Kanemitsu , MD1; Kohei Shitara , MD2; Junki Mizusawa, ME1; Tetsuya Hamaguchi, MD, PhD3; Dai Shida , MD, PhD1; Koji Komori , MD, PhD4; Satoshi Ikeda, MD, PhD5; Hitoshi Ojima, MD, PhD6; Hideyuki Ike, MD, PhD7; Akio Shiomi, MD8; Jun Watanabe , MD, PhD9; Yasumasa Takii , MD10; Takashi Yamaguchi, MD11; Kenji Katsumata, MD, PhD12; Masaaki Ito , MD, PhD2; Junji Okuda, MD, PhD13; Ryoji Hyakudomi, MD14; Yasuhiro Shimada, MD15; Hiroshi Katayama, MD1; Haruhiko Fukuda, MD1; and JCOG Colorectal Cancer Study Group

doi : 10.1200/JCO.20.02447

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1098-1107.

It remains controversial whether primary tumor resection (PTR) before chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic primary tumor and synchronous unresectable metastases.

خرید پکیج و مشاهده آنلاین مقاله

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

J. Randolph Hecht , MD1; Sara Lonardi , MD2; Johanna Bendell, MD3; Hao-Wen Sim , MBBS, FRACP4,5; Teresa Macarulla, MD6; Charles D. Lopez, MD, PhD7; Eric Van Cutsem , MD, PhD8; Andres J. Mu?oz Martin , MD, PhD9; Joon Oh Park , MD, PhD10; Richard Greil , MD11; Hong Wang, PhD12; Rebecca R. Hozak, PhD12; Ivelina Gueorguieva, PhD12; Yong Lin, PhD13; Sujata Rao, MD12; and Baek-Yeol Ryoo , MD14

doi : 10.1200/JCO.20.02232

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1108-1118.

SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma (PDAC).

خرید پکیج و مشاهده آنلاین مقاله

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Kishan K. Patel, BS1; Smith Giri, MD, MHS2; Terri L. Parker, MD1; Noffar Bar, MD1; Natalia Neparidze, MD1; and Scott F. Huntington, MD, MPH, MSc1,3

doi : 10.1200/JCO.20.01849

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1119-1128.

The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd). However, daratumumab is a costly treatment and is administered indefinitely until disease progression. Therefore, it is unclear whether it is cost-effective to use daratumumab in the first-line setting compared with reserving its use until later lines of therapy.

خرید پکیج و مشاهده آنلاین مقاله

Burkitt Lymphoma International Prognostic Index

Adam J. Olszewski, MD1; Lasse H. Jakobsen, PhD2; Graham P. Collins, MD, DPhil3; Kate Cwynarski, MBBS, PhD4; Veronika Bachanova, MD5; Kristie A. Blum, MD6; Kirsten M. Boughan, DO7; Mark Bower, MD8; Alessia Dalla Pria, MD8; Alexey Danilov, MD, PhD9; Kevin A. David, MD10; Catherine Diefenbach, MD11; Fredrik Ellin, MD, PhD12; Narendranath Epperla, MD, MS13; Umar Farooq, MD14; Tatyana A. Feldman, MD15; Alina S. Gerrie, MD, MPH16; Deepa Jagadeesh, MD17; Manali Kamdar, MD, MBBS18; Reem Karmali, MD, MSc19; Shireen Kassam, MBBS, PhD20; Vaishalee P. Kenkre, MD21; Nadia Khan, MD22; Seo-Hyun Kim, MD23; Andreas K. Klein, MD24; Izidore S. Lossos, MD25; Matthew A. Lunning, DO26; Peter Martin, MD, MS27; Nicolas Martinez-Calle, MD, PhD28; Silvia Montoto, MD29; Seema Naik, MD30; Neil Palmisiano, MD, MS31; David Peace, MD32; Elizabeth H. Phillips, MBBS, BSc33; Tycel J. Phillips, MD34; Craig A. Portell, MD35; Nishitha Reddy, MD, MBBS36; Anna Santarsieri, MBBS37; Maryam Sarraf Yazdy, MD38; Knut B. Smeland, MD39; Scott E. Smith, MD, PhD40; Stephen D. Smith, MD41; Suchitra Sundaram, MD42; Adam S. Zayac, MD1; Xiao-Yin Zhang, PhD3; Catherine Zhu, MD4; Chan Y. Cheah, MBBS43; Tarec C. El-Galaly, MD44; Andrew M. Evens, DO, MSc10 on behalf of The Burkitt Lymphoma International Prognostic Index consortium

doi : 10.1200/JCO.20.03288

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1129-1138.

Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches.

خرید پکیج و مشاهده آنلاین مقاله

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Hervé Avet-Loiseau , MD1; Jesus San-Miguel , MD2; Tineke Casneuf, PhD3; Shinsuke Iida , MD4; Sagar Lonial , MD5; Saad Z. Usmani , MD6; Andrew Spencer, MD7; Philippe Moreau, MD8; Torben Plesner, MD9; Katja Weisel, MD10; Jon Ukropec, PhD11; Christopher Chiu, PhD12; Sonali Trivedi, PhD12; Himal Amin, BS13; Maria Krevvata, PhD12; Priya Ramaswami, MSPH14; Xiang Qin, MS12; Mia Qi, PhD13; Steven Sun, PhD13; Ming Qi, MD12; Rachel Kobos, MD13; and Nizar J. Bahlis , MD15

doi : 10.1200/JCO.20.01814

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1139-1149.

In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies.

خرید پکیج و مشاهده آنلاین مقاله

CanDirect: Effectiveness of a Telephone-Supported Depression Self-Care Intervention for Cancer Survivors

Jane McCusker, MD, DrPH1; Jennifer M. Jones, PhD2; Madeline Li, MD, PhD2; Rosana Faria, MPs3; Mark J. Yaffe, BSc, MDCM, MClSc3; Sylvie D. Lambert, PhD4; Antonio Ciampi, PhD1; Eric Belzile, MSc1; and Manon de Raad, BComm1

doi : 10.1200/JCO.20.01802

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1150-1161.

Depression in post-treatment cancer survivors is common and can impair quality of life. CanDirect is a novel, telephone-delivered depression self-care intervention for cancer survivors. We conducted a randomized controlled superiority trial to compare CanDirect with usual care (UC) in this population.

خرید پکیج و مشاهده آنلاین مقاله

This Is Not Happening

Sarah J. Ramer , MD, MS1

doi : 10.1200/JCO.20.03298

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1162-1164.

خرید پکیج و مشاهده آنلاین مقاله

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

Sonali M. Smith, MD1; Kerri Wachter , BS2; Howard A. Burris III, MD3; Richard L. Schilsky , MD2; Daniel J. George , MD4; Douglas E. Peterson , DMD, PhD5; Melissa L. Johnson, MD3; Merry Jennifer Markham, MD, FACP, FASCO6; Kathryn F. Mileham, MD7; Muhammad S. Beg , MD8; Johanna C. Bendell, MD3; Robert Dreicer, MD, MS, MACP9; Vicki L. Keedy , MD10; Randall J. Kimple , MD, PhD11; Miriam A. Knoll, MD12; Noelle LoConte , MD11; Helen MacKay, MD, MS, MACP13; Jane Lowe Meisel, MD14; Timothy J. Moynihan, MD15; Daniel A. Mulrooney , MD16; Therese Marie Mulvey , MD17; Olatoyosi Odenike, MD1; Nathan A. Pennell , MD, PhD18; Katherine Reeder-Hayes , MD, MBA, MS19; Cardinale Smith , MD, PhD20; Ryan J. Sullivan , MD17; and Robert Uzzo, MD, MBA21

doi : 10.1200/JCO.20.03420

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1165-1184.

خرید پکیج و مشاهده آنلاین مقاله